Aimed Alliance recently sent a letter urging the Virginia House Labor and Commerce Committee to reconsider House Bill 483, which would create a Prescription Drug Affordability Board (PDAB). The letter outlines why upper payment limits set by PDABs do not directly reduce patients’ out‑of‑pocket costs and may even worsen access due to increased utilization management tactics and formulary changes. The letter also provides examples of implementation challenges in states like Maryland, New Hampshire, and Oregon, underscoring that PDABs have proven costly, complex, and ineffective in producing measurable savings. Read the letter here.
Last Updated on February 2, 2026 by Aimed Alliance
